Coltac Therapeutics

Company Overview

Snapshot

Founded in January 2022, Coltac Therapeutics operates with 1–10 employees. The company has raised $5 million across two funding rounds.

Business overview

Coltac Therapeutics is a preclinical pharmaceutical company focused on drug discovery within the Health Tech & Life Sciences sector. The company develops and researches solutions for identifying next-generation molecular glues by leveraging its proprietary bacteria-based, synthetic positive selection screening system. Its core technology aims to advance biopharmaceutical and biotechnology applications, particularly in oncology and protein-related drug discovery, serving the healthcare and life sciences markets.

Company Intelligence Q&A

What is Coltac Therapeutics' primary focus?

Coltac Therapeutics is primarily focused on preclinical pharmaceutical development, specifically in discovering next-generation molecular glues using a bacteria-based, synthetic positive selection screening system.

When was Coltac Therapeutics founded?

Coltac Therapeutics was founded in January 2022.

How much capital has Coltac Therapeutics raised to date?

Coltac Therapeutics has raised $5 million in total funding.

Which investor participated in Coltac Therapeutics' seed funding round?

In April 2022, Coltac Therapeutics secured seed funding from aMoon Fund, which was the sole disclosed investor in that round.

What industries does Coltac Therapeutics serve?

Coltac Therapeutics serves the biopharmaceutical and biotechnology industries, with a focus on drug discovery and oncology.